- The disease
- Xeroderma Pigmentosum (XP) is a rare inherited condition in which the body cannot adequately repair damage to DNA caused by ultraviolet (UV) light. Affected individuals develop severe sunburn from minimal sun exposure and have a greatly elevated risk of skin cancers. There is no approved therapy that corrects the underlying DNA repair defect; current management relies on strict sun avoidance and regular surveillance for skin cancers.
- What the asset is trying to do
- Afamelanotide (SCENESSE) is a synthetic peptide that acts as an agonist at the melanocortin-1 receptor (MC1R), a protein involved in regulating skin pigmentation. In XP, the drug is being studied for a proposed secondary effect: whether MC1R activation can enhance residual DNA repair capacity in skin cells, beyond its established role in stimulating melanin production. This represents a mechanistically distinct approach from sun-protection measures, which address exposure rather than the underlying cellular repair deficit.
- What the trial is measuring, and why it matters
- The two Phase 2 XP studies (NCT05370235 and NCT05159752) are each enrolling six patients to evaluate the safety and efficacy of afamelanotide in XP subtypes (per ClinicalTrials.gov NCT05370235 and NCT05159752). Primary completion dates were set at June 2024 and March 2024 respectively (per ClinicalTrials.gov), and both trials carry an "Unknown" status, meaning their current operational state has not been recently verified on the registry. Typical endpoints in XP photoprotection studies include measures of UV-induced skin damage, pigmentation response, and tolerability, though the specific primary endpoints for these trials are .
- Efficacy benchmarks in this setting
- No therapy is currently approved specifically for XP to address its DNA repair deficit. In the broader context of photoprotection in porphyria, afamelanotide's approved indication, the pivotal Phase 3 trial in Erythropoietic Protoporphyria (EPP) showed that treated patients experienced a median of 69.4 minutes of sun exposure without pain in the sixth month compared to 0 minutes for placebo patients (per Langendonk et al., New England Journal of Medicine, 2015). There are no directly comparable approved-therapy benchmarks for the XP DNA-repair endpoint, and the small sample sizes in the current Phase 2 XP studies (six patients each, per ClinicalTrials.gov NCT05370235 and NCT05159752) mean any figures generated would not be statistically comparable to data from larger pivotal programmes.